公开(公告)号：US20140186355A1

公开(公告)日：2014-07-03

申请号：US14107314

申请日：2013-12-16

Applicant: UCB Pharma S.A.

Inventor： Ralph Adams ,  Andrew George Popplewell ,  Stephen Edward Rapecki

IPC: C07K16/24

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract translation: 本发明涉及对IL-17A和IL-17F的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途和产生所述抗体分子的方法。

公开(公告)号：US20140178387A1

公开(公告)日：2014-06-26

申请号：US14186074

申请日：2014-02-21

Applicant: UCB Pharma S.A.

Inventor： NEIL GOZZARD ,  ALASTAIR DAVID GRIFFITHS LAWSON ,  DANIEL JOHN LIGHTWOOD ,  ROGER THOMAS PALFRAMAN ,  BRYAN JOHN SMITH ,  KERRY LOUISE TYSON

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K9/0078 ,  A61K39/395 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/544 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract translation: 本发明涉及对人IL-13的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。

公开(公告)号：US08710054B2

公开(公告)日：2014-04-29

申请号：US13681840

申请日：2012-11-20

Applicant: UCB Pharma, S.A.

Inventor： Rikki Peter Alexander ,  Pavandeep Singh Aujla ,  Karen Viviane Lucile Crepy ,  Anne Marie Foley ,  Richard Jeremy Franklin

IPC: A61K31/535 ,  C07D413/14

CPC classification number: C07D495/04 ,  C07D513/04 ,  C07D513/12 ,  C07D519/00

Abstract: A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Abstract translation: 一系列在二位被取代的吗啉-4-基部分取代的6,7-二氢[1,3]噻唑并[5,4-c]吡啶-4（5H） - 酮衍生物是 因此PI3激酶的选择性抑制剂在医学中是有益的，例如在治疗炎症，自身免疫，心血管，神经变性，代谢，肿瘤，伤害性或眼科疾病中。

公开(公告)号：US20130203968A1

公开(公告)日：2013-08-08

申请号：US13854455

申请日：2013-04-01

Applicant: Amgen Inc. ,  UCB Pharma S.A.

Inventor： Martin K. Robinson ,  Christopher J. Paszty ,  Alistair James Henry ,  Alastair Lawson ,  Andy Popplewell

IPC: C07K16/18

CPC classification number: C07K16/18 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided.

Abstract translation: 提供了与硬骨素结合剂（例如能够结合硬化蛋白的抗体和多肽）相关的组合物和方法。

公开(公告)号：US20130079330A1

公开(公告)日：2013-03-28

申请号：US13681840

申请日：2012-11-20

Applicant: UCB Pharma, S.A.

Inventor： Rikki Peter Alexander ,  Pavandeep Singh Aujla ,  Karen Viviane Lucile Crepy ,  Anne Marie Foley ,  Richard Jeremy Franklin

IPC: C07D495/04

CPC classification number: C07D495/04 ,  C07D513/04 ,  C07D513/12 ,  C07D519/00

Abstract: A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Abstract translation: 一系列在二位被取代的吗啉-4-基部分取代的6,7-二氢[1,3]噻唑并[5,4-c]吡啶-4（5H） - 酮衍生物是 因此PI3激酶的选择性抑制剂在医学中是有益的，例如在治疗炎症，自身免疫，心血管，神经变性，代谢，肿瘤，伤害性或眼科疾病中。

公开(公告)号：US20240209075A1

公开(公告)日：2024-06-27

申请号：US18333425

申请日：2023-06-12

Applicant: UCB PHARMA S.A.

Inventor： David G. Winkler ,  Jiye Shi ,  John Latham

IPC: C07K16/22 ,  A61K47/64 ,  C07K14/475 ,  C07K14/51 ,  C07K16/18 ,  G01N33/50 ,  G01N33/577 ,  G01N33/68

CPC classification number: C07K16/22 ,  A61K47/643 ,  A61K47/646 ,  C07K14/475 ,  C07K14/51 ,  C07K16/18 ,  G01N33/6854 ,  C07K2317/76 ,  G01N33/50 ,  G01N33/577 ,  G01N33/68 ,  G01N33/6863 ,  G01N2333/4704

Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.

公开(公告)号：US11851483B2

公开(公告)日：2023-12-26

申请号：US15534635

申请日：2015-12-11

Applicant: AMGEN INC. ,  UCB PHARMA, S.A.

Inventor： Martyn Kim Robinson ,  Michael Stuart Ominsky ,  Xiaodong Li ,  Hua Zhu Ke

IPC: A61K39/395 ,  C07K16/22 ,  A61P19/08 ,  A61P19/10 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61P19/08 ,  A61P19/10 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/94

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.

公开(公告)号：US11339214B2

公开(公告)日：2022-05-24

申请号：US16248845

申请日：2019-01-16

Applicant: UCB PHARMA, S.A.

Inventor： Mariangela Spitali ,  Jonathan Symmons ,  Richard Whitcombe ,  Mark Robert Pearce-Higgins

IPC: C07K1/18 ,  C07K16/24 ,  C07K1/36

Abstract: The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step.

公开(公告)号：US10759844B2

公开(公告)日：2020-09-01

申请号：US14697092

申请日：2015-04-27

Applicant: UCB PHARMA S.A.

Inventor： David Paul Humphreys

IPC: A61K39/00 ,  C07K16/00

Abstract: The present disclosure provides an antibody or antibody fragment comprising at least one Fab molecule, wherein the light chain variable region, VL and the heavy chain region, VH of the Fab molecule are linked by one or more disulfide bonds, and use of the same in treatment or prophylaxis.

公开(公告)号：US20200157204A1

公开(公告)日：2020-05-21

申请号：US16717671

申请日：2019-12-17

Applicant: UCB PHARMA S.A.

Inventor： David Paul Humphreys ,  Ralph Adams ,  James Heads ,  Shirley Jane Peters

IPC: C07K16/24 ,  A61K39/395 ,  C07K16/00

Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.